Poly(ADP-ribose) polymerase inhibitor PJ-34 reduces mesenteric vascular injury induced by experimental cardiopulmonary bypass with cardiac arrest
1 Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany; 2 Department of Visceral, Thoracic and Vascular Surgery, Carl Gustav Carus University Hospital, Dresden, Germany; and 3 Department of Internal Medicine, Semmelweis University, Budapest, Hungary Submitted 10 October 2004...
Gespeichert in:
Veröffentlicht in: | American journal of physiology. Heart and circulatory physiology 2005-06, Vol.288 (6), p.H2972-H2978 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | 1 Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany; 2 Department of Visceral, Thoracic and Vascular Surgery, Carl Gustav Carus University Hospital, Dresden, Germany; and 3 Department of Internal Medicine, Semmelweis University, Budapest, Hungary
Submitted 10 October 2004
; accepted in final form 17 January 2005
The aim of this study was to investigate effects of poly(ADP-ribose) polymerase (PARP) inhibition on mesenteric vascular function and metabolism in an experimental model of cardiopulmonary bypass (CPB) with cardiac arrest. Twelve anesthetized dogs underwent 90-min hypothermic CPB. After 60 min of cardiac arrest, reperfusion was started for 40 min following application of either saline vehicle (control, n = 6) or a potent PARP inhibitor, PJ-34 (10 mg/kg iv bolus and 0.5 mg·kg 1 ·min 1 infusion for 20 min, n = 6). PJ-34 led to better recovery of cardiac output (2.2 ± 0.1 vs. 1.8 ± 0.2 l/min in control) and mesenteric blood flow (175 ± 38 vs. 83 ± 4 ml/min, P < 0.05 vs. control) after reperfusion. The impaired vasodilator response of the superior mesenteric artery to acetylcholine, assessed in the control group after CPB (32.8 ± 3.3 vs. 57.6 ± 6.6% at baseline, P < 0.05), was improved by PJ-34 (50.3 ± 3.6 vs. 54.3 ± 4.1% at baseline, P < 0.05 vs. control). Although plasma nitrate/nitrite concentrations were not significantly different between groups, mesenteric nitric oxide synthase activity was increased in the PJ-34 group ( P < 0.05). Moreover, the treated group showed a marked attenuation of mesenteric venous plasma myeloperoxidase levels after CPB compared with the control group (75 ± 1 vs. 135 ± 9 ng/ml, P < 0.05). Pharmacological PARP inhibition protects against development of post-CPB mesenteric vascular dysfunction by improving hemodynamics, restoring nitric oxide production, and reducing neutrophil adhesion.
endothelial function; nitric oxide; neutrophil adhesion; hemodynamics
Address for reprint requests and other correspondence: T. B. Andrási, Dept. of Visceral, Thoracic and Vascular Surgery, Carl Gustav Carus Univ. Hospital, Fetscherstrasse 74, Haus 59, 01307 Dresden, Germany (E-mail: tean74{at}hotmail.com ) |
---|---|
ISSN: | 0363-6135 1522-1539 |
DOI: | 10.1152/ajpheart.01039.2004 |